Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REIMAGINE5: CagriSema versus tirzepatide in adults with inadequately controlled type 2 diabetes mellitus
MOH_2024-09-05_013627Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing CagriSema arm with Tirzepatide arm (2 arms). Started Sep 2024; status: completed.
02
Drugs
CagriSematirzepatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on MOH_2024-09-05_013627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-09-05_013627.